文献速递睡眠呼吸障碍

自动滴定与固定CPAP治疗肥胖低通气综合征合并重度OSA的初步随机非劣效性试验

A Pilot Randomised Non-Inferiority Trial of Auto-Titrating Versus Fixed Continuous Positive Airway Pressure for Obesity Hypoventilation Syndrome With Severe Obstructive Sleep Apnoea.
PubMed 文献 · Respirology · 2025-11-02

主要结局为PaCO2变化,APAP对比fCPAP的非劣效性检验无定论,部分结局倾向fCPAP,提示APAP应谨慎使用。

要点

  • APAP与fCPAP均降低PaCO2,但非劣效性检验无定论。
  • 依从性和睡眠质量改善倾向fCPAP。
  • APAP在OHS+sOSA中应谨慎使用,需更大样本研究确认。

核心结论

  • 初步试验提示APAP对比fCPAP的非劣效性检验无定论,部分结局倾向fCPAP,APAP在OHS+sOSA中应谨慎使用。

主要发现

  • fCPAP组PaCO2降低5.7±1.6 mmHg,APAP组降低4.1±2.8 mmHg。
  • APAP对比fCPAP的ΔPaCO2差异为-1.7 mmHg(95%CI -5.0至1.6 mmHg),非劣效性检验无定论。
  • 两组平均依从性均超过4小时,但25%随机化参与者未完成试验。
  • 依从性和睡眠质量改善倾向fCPAP,其他结局相当。

关键数值与推荐

  • 非劣效性界值为-2.5 mmHg,需样本量82例以证明非劣效性。
  • 初步试验计划招募至多44例参与者。

临床怎么用

  • 基于初步数据,OHS+sOSA患者使用APAP应谨慎,fCPAP仍为优选。

局限性

  • 初步试验样本量小,未达到证明非劣效性所需样本量。
  • 招募和保留存在挑战,25%随机化参与者未完成试验。
  • 研究不足以确认APAP的非劣效性,需更大样本研究并调整方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Fixed CPAP (fCPAP) is the preferred first-line ventilatory therapy in patients with obesity hypoventilation syndrome with severe obstructive sleep apnoea (OHS + sOSA). Auto-titrating CPAP (APAP) is not recommended but has not been systematically evaluated in this population. Our pilot study aimed to provide feasibility data for a larger comparative effectiveness trial to determine whether APAP is non-inferior to fCPAP for improving hypercapnic respiratory failure. METHODS: Participants with OHS + sOSA were randomised to either APAP or fCPAP for 3 months. The primary outcome was the change in PaCO2. Secondary outcomes included changes in quality of life and cardiovascular biomarkers. A sample size of 82 was needed to demonstrate non-inferiority of APAP compared to fCPAP (assuming a non-inferiority margin of -2.5 mmHg). To assess feasibility we aimed to recruit up to 44 participants in this pilot trial. RESULTS: Twenty-eight of 84 screened participants were randomised (Mean ± SD: Age 55 ± 12.5 years, BMI 54 ± 9.9 kg m-2, PaCO2 49 ± 2.6 mmHg, AHI 88 ± 31 events/h) to APAP (n = 15) or fCPAP (n = 13). Mean adherence exceeded 4 h in both groups; however 25% of randomised participants did not complete the trial. Both treatments reduced PaCO2 (fCPAP: -5.7 ± 1.6 mmHg, APAP: -4.1 ± 2.8 mmHg). Test of non-inferiority for APAP versus fCPAP was inconclusive (mean ΔPaCO2 difference = -1.7 mmHg (95% CI -5.0 to 1.6 mmHg)). Adherence and sleep quality improvements favoured fCPAP, while other outcomes were comparable. CONCLUSION: The pilot study highlighted important challenges with recruitment and retention. While the study is not powered to confirm the non-inferiority of APAP, some outcomes appeared to favour fCPAP and APAP use in OHS + sOSA should be approached cautiously. A larger study with protocol modifications is required to confirm these preliminary findings. TRIAL REGISTRATION: ACTRN12618000379213. https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=374259. Assessing the Efficacy of Auto-titrating versus Fixed Continuous Positive Airway Pressure in Obesity Hypoventilation Syndrome.

来源:Respirology,查看原文。版权归原作者所有。

引用

  1. Zheng Y, Piper A, Wong K, et al. A Pilot Randomised Non-Inferiority Trial of Auto-Titrating Versus Fixed Continuous Positive Airway Pressure for Obesity Hypoventilation Syndrome With Severe Obstructive Sleep Apnoea. Respirology. 2025. PMID: 41177916. doi:10.1002/resp.70151

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。